<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90688">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01871753</url>
  </required_header>
  <id_info>
    <org_study_id>BiRT study</org_study_id>
    <secondary_id>2012-003857-26</secondary_id>
    <nct_id>NCT01871753</nct_id>
  </id_info>
  <brief_title>The Bacteriuria in Renal Transplantation (BiRT) Study: A Trial Comparing Antibiotics Versus no Treatment in the Prevention of Symptomatic Urinary Tract Infection in Kidney Transplant Recipients With Asymptomatic Bacteriuria</brief_title>
  <acronym>BiRT</acronym>
  <official_title>The Bacteriuria in Renal Transplantation (BiRT) Study: A Prospective, Randomized, Parallel-group, Multicenter, Open-label, Superiority Trial Comparing Antibiotics Versus no Treatment in the Prevention of Symptomatic Urinary Tract Infection in Kidney Transplant Recipients With Asymptomatic Bacteriuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Necker Enfants-Malades, Université de Paris Descartes, APHP, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Régional Universitaire de Lille, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Brugmann</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Charleroi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitair Ziekenhuis Gent, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Epicura, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Liege</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare antibiotics versus no-treatment in kidney transplant
      recipients with asymptomatic bacteriuria.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>cumulative incidence of a first episode of symptomatic urinary tract infection</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of a first episode of pyelonephritis</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clearance of asymptomatic bacteriuria</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of new episodes of asymptomatic bacteriuria</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>graft function/graft survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of graft rejection</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>utility of a control urine culture for diagnosis of asymptomatic bacteriuria in kidney transplant recipients</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of antimicrobial resistance in bacteria responsible for symptomatic urinary tract infections</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total number of days of antimicrobial therapy</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost of antimicrobial treatment for asymptomatic bacteriuria and symptomatic urinary tract infection</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of hospitalizations for asymptomatic bacteriuria and symptomatic urinary tract infection treatment</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total number of symptomatic urinary tract infections in both groups</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Asymptomatic Bacteriuria</condition>
  <condition>Bacteriuria</condition>
  <condition>Urinary Tract Infections</condition>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Antibiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results  (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no antibiotics delivered in case of asymptomatic bacteriuria, independently of the number of asymptomatic episodes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anti-Infective Agents</intervention_name>
    <description>10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results  (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up)</description>
    <arm_group_label>Antibiotics</arm_group_label>
    <other_name>Anti-Infective Agents: not applicable - no specific agent</other_name>
    <other_name>The choice of antimicrobial agent is at the discretion of the physician, and is based on the antibiogram results</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Kidney transplant recipient with asymptomatic bacteriuria after the first two months
             post-transplantation

        Exclusion Criteria:

          -  Pregnant women or women who wish to become pregnant during the course of the study

          -  Presence of indwelling urinary devices such as urethral catheter, ureteral catheter,
             nephrostomy and/or suprapubic catheter

          -  Combined transplantation (liver-kidney, lung-kidney, heart-kidney)

          -  Urinary tract surgery during the last two months

          -  Surgical urological procedure planned in the next 2 weeks

          -  Neutropenia (≤ 500 neutrophils/mm3)

          -  Important intensification of immunosuppression (Solumedrol bolus and/or use of
             thymoglobulin) or any other treatment of an acute graft rejection in the last two
             months

          -  Use of antibiotics at the time of the asymptomatic bacteriuria (except for prevention
             of Pneumocystis jirovecii)

          -  End-Stage Renal Disease (ESRD) requiring dialysis

          -  Non-functioning native bladder (e.g. bladder dysfunction requiring intermittent
             self-catheterization, orthotopic ileal neobladder)

          -  Recurrent acute graft pyelonephritis (≥ 2 episodes in the last year)

          -  Kidney transplant recipients who could not return for regular follow-up
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien Coussement, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hôpital Universitaire Erasme, Brussels, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien Coussement, MD</last_name>
    <phone>003225553111</phone>
    <email>julien.coussement@erasme.ulb.ac.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Abramowicz, MD, PhD</last_name>
      <phone>+32.3.821.34.35</phone>
      <email>dabram@ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Daniel Abramowicz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Louis Bosmans, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Herman Goossens, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Epicura</name>
      <address>
        <city>Baudour</city>
        <zip>7331</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lidia Ghisdal, MD, PhD</last_name>
      <phone>003265768111</phone>
      <email>lghisdal@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Lidia Ghisdal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Coussement, MD</last_name>
      <phone>+32.2.555.30.49</phone>
      <email>julien.coussement@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Julien Coussement, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédérique Jacobs, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine Roisin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nilufer Broeders, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mireille Kianda, MD</last_name>
      <phone>+32.2.477.26.41</phone>
      <email>mireille.kianda@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Mireille Kianda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel - Vrije Universiteit Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl M Wissing, MD, PhD</last_name>
      <phone>+32.2.477.60.55</phone>
      <email>karlmartin.wissing@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Karl M Wissing, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6110</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Madhoun, MD</last_name>
      <phone>+32.7.192.11.82</phone>
      <email>philippe.madhoun@chu-charleroi.be</email>
    </contact>
    <investigator>
      <last_name>Philippe Madhoun, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Peeters, MD</last_name>
      <phone>+32.9.332.27.42</phone>
      <email>patrick.peeters@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Patrick Peeters, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Van Laecke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Weekers, MD</last_name>
      <phone>+32.4.366.74.05</phone>
      <email>l.weekers@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Laurent Weekers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Hazzan, MD, PhD</last_name>
      <phone>+33.3.20.44.67.70</phone>
      <email>mhazzan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marc Hazzan, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Kidney Transplantation, Hôpital Necker Enfants-Malades, Université de Paris Descartes, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Scemla, MD</last_name>
      <phone>+33.1.44.49.54.41</phone>
      <email>anne.scemla@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Scemla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.birtstudy.com</url>
    <description>trial website</description>
  </link>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 23, 2014</lastchanged_date>
  <firstreceived_date>May 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasme University Hospital</investigator_affiliation>
    <investigator_full_name>Dr Coussement Julien</investigator_full_name>
    <investigator_title>Julien Coussement, MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacteriuria</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
